Simcere Pharmaceutical Group Limited(2096.HK) is rapidly transitioning to an innovation and R&D-driven pharmaceutical company, with a mission of “providing today’s patients with medicines of the future.” It has established the State Key Laboratory of Translational Medicine and Innovative Drug Development. Simcere focuses on three therapeutic areas: oncology, central nervous system diseases and autoimmune diseases, with a diversified product portfolio and industry-leading capabilities. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading pharmaceutical companies and biotechnology companies, in an effort to bring more global life science breakthroughs to China. We have been continuously recognized as one of the “Top 10 Innovative Pharmaceutical Enterprises in China” and “Top 100 Pharmaceutical Manufacturing Enterprises of China ”.

Milestones

1995
2001
2003
2007
2015
2018
2019
2020

Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
Acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, started to build our own research and development team
Acquired the entire equity interest in former Simcere Dongyuan, which further enriched our product portfolio and production capabilities
Was listed on the NYSE on April 20, 2007, making us the first bio and chemical pharmaceutical company in China to be listed on the NYSE. Simcere completed its privatization in 2013
The Ministry of Science and Technology approved the establishment of the State Key Laboratory of Translational Medicine and Innovative Drug Development
Shanghai R&D center established
Boston R&D Center established
Listed on the Hong Kong Stock Exchange (02096.HK)

1995
Established Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals
2001
Acquired a controlling interest in Hainan Simcere and manufacturing capabilities of pharmaceuticals, started to build our own research and development team
2003
Acquired the entire equity interest in former Simcere Dongyuan, which further enriched our product portfolio and production capabilities
2007
Was listed on the NYSE on April 20, 2007, making us the first bio and chemical pharmaceutical company in China to be listed on the NYSE. Simcere completed its privatization in 2013
2015
The Ministry of Science and Technology approved the establishment of the State Key Laboratory of Translational Medicine and Innovative Drug Development
2018
Shanghai R&D center established
2019
Boston R&D Center established
2020
Listed on the Hong Kong Stock Exchange (02096.HK)

Management Team

: Ren Jinsheng

Chairman of the Board and
Chief Executive Officer

: Wan Yushan

Executive Director and
Chief Financial Officer

: Tang Renhong, PhD

Executive Director and
Executive Vice President

: Bijoyesh Mookerjee, MD

Chief Medical Officer, Oncology

: Zhou Gaobo

Chief Investment Officer

: Kevin Oliver, PhD

Senior Vice President

: Danny Chen, PhD

Senior Vice President

: Andrew Zhu

Senior Vice President

: Cheng Xianghua

Vice President

: Qian Haibo, PhD

Vice President

: Shi Ruiwen, PhD

Vice President

: Wang Feng，PhD

Vice President

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

: Integrity

: Excellence

: Perseverance

: Proactivity

: Customer-First

Simcere CI

The name “Simcere” comes from the word “sincere”, which embodies our main principle of treating people with sincerity.
On the left side of our logo is Simcerer running against the wind, representing the spirit of unremitting endeavor and the courage to pursue excellence.
The color green symbolizes life, health and vitality.

Milestones

Management Team

Ren Jinsheng

Wan Yushan

Tang Renhong, PhD

Bijoyesh Mookerjee, MD

Zhou Gaobo

Kevin Oliver, PhD

Danny Chen, PhD

Andrew Zhu

Cheng Xianghua

Qian Haibo, PhD

Shi Ruiwen, PhD

Wang Feng，PhD

Mission

Providing Today’s Patients with Medicines of the Future

Core Values

Simcere CI